ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Eukaryotic Gene Expression
インパクトファクター: 1.841 5年インパクトファクター: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN 印刷: 1045-4403
ISSN オンライン: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v10.i2.50
20 pages

Molecular Mechanisms of Tumor-Bone Interactions in Osteolytic Metastases

John M. Chirgwin
Division of Endocrinology, Department of Medicine, University of Texas Health Science Center at San Antonio; and Research Service, Veterans Administration Medical Center, San Antonio, TX 78229-3900
Theresa A. Guise
Division of Endocrinology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900

要約

In patients with advanced disease, several cancer types frequently metastasize to the skeleton, where they cause bone destruction. Osteolytic metastases are incurable and cause pain, hypercalcemia, fracture, and nerve compression syndromes. It was proposed over a century ago that certain cancers, such as that of the breast, preferentially metastasize to the favorable microenvironment provided by bone. Bone matrix is a rich store of immobilized growth factors that are released during bone resorption. Histological analysis of osteolytic bone metastases indicates that the bone destruction is mediated by the osteoclast rather than directly by the tumor cells. These observations suggest a vicious cycle driving the formation of osteolytic metastases: tumor cells secrete factors stimulating osteoclasts through adjacent bone marrow stromal cells; osteoclastic resorption in turn releases growth factors from the bone matrix; finally, locally released growth factors activate the tumor cells. This vicious cycle model has now been confirmed at the molecular level. In particular, transforming growth factor β (TGFβ) is abundant in bone matrix and released as a consequence of osteoclastic bone resorption. Bone-derived TGFβ plays an integral role in promoting the development and progression of osteolytic bone metastases by inducing tumor production of parathyroid hormone-related protein (PTHrP), a known stimulator of osteoclastic bone resorption. In breast cancer cells TGFβ appears to stimulate PTHrP secretion by a posttranscriptional mechanism through both Smad and p38 mitogen activated protein (MAP) kinase signaling pathways. Osteolytic metastases can be suppressed in vivo by inhibition of bone resorption, blockade of TGFβ signaling in tumor cells, and by neutralization of PTHrP. Other factors released from bone matrix may also act on tumor cells in bone, which in turn may produce other factors that stimulate bone resorption, following the vicious cycle paradigm established for TGFβ and PTHrP. An understanding at the molecular level of the mechanisms of osteolytic metastasis will result in more effective therapies for this devastating complication of cancer.


Articles with similar content:

Parathyroid Hormone-Related Protein in Prostate Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.15, 2005, issue 1
Subhash Kukreja, Farrokh Asadi
Matrix Metalloproteinase Control of Capillary Morphogenesis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.18, 2008, issue 3
Andrew Putnam, Steven C. George, Cyrus M. Ghajar
Cell Signaling Pathways Related to Epithelial Mesenchymal Transition in Cancer Metastasis
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 1
Sevinc Inan, Mürvet Hayran
N-myc Downstream-Regulated Gene 1 and Endometriosis: A Minireview
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Chongdong Liu, Tong Lou, Zhenyu Zhang
Immune Function of the Decoy Receptor Osteoprotegerin
Critical Reviews™ in Immunology, Vol.22, 2002, issue 3
Elizabeth J. Ryan, Asa K. Bengtsson